About Bacs-Kiskun Megyei Korhaz, SZTE AOK Oktato Korhaza, Onkoradiologiai Kozpont
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
6
Pfizer
2
Puma Biotechnology, Inc.
2
Genentech, Inc.
1
Institut de Recherches Internationales Servier
1
SynCore Biotechnology Co., Ltd.
1
Taiho Oncology, Inc.
1
Clinical Trials at Bacs-Kiskun Megyei Korhaz, SZTE AOK Oktato Korhaza, Onkoradiologiai Kozpont
During the past decade, Bacs-Kiskun Megyei Korhaz, SZTE AOK Oktato Korhaza, Onkoradiologiai Kozpont conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 7 clinical trials were completed, i.e. on
average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
2009-02-04
2018-06-03
Completed
233
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
2009-07-09
2019-10-04
Completed
2,840
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
2011-11-08
2028-11-30
Active, not recruiting
4,804
An Observational Study of First-Line Capecitabine Based Chemotherapy in Participants With Metastatic Colorectal Cancer
2011-07-01
2014-12-01
Completed
882
A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)
2014-02-24
2020-06-27
Completed
707
A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)
2014-11-12
2017-03-13
Completed
334
An Observational Study of Continued Bevacizumab Plus Chemotherapy Until First Progression in Participants With Metastatic Colorectal Cancer (CRC)
2015-01-13
2017-12-29
Completed
300
EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX
2018-10-16
2021-10-08
Completed
218
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Bacs-Kiskun Megyei Korhaz, SZTE AOK Oktato Korhaza, Onkoradiologiai Kozpont" #1 sponsor was "Hoffmann-La Roche" with 6 trials, followed by "Pfizer" with 2 trials
sponsored, "Puma Biotechnology, Inc." with 2 trials sponsored, "Genentech, Inc." with 1 trials sponsored and "Institut de Recherches Internationales Servier"
with 1 trials sponsored. Other sponsors include -3 different institutions and
companies that sponsored additional 7 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Bacs-Kiskun Megyei Korhaz, SZTE AOK Oktato Korhaza, Onkoradiologiai Kozpont"
#1 collaborator was "Breast International Group" with 2 trials as a collaborator, "ADIR, a Servier Group company" with 1 trials as a collaborator, "Austrian Breast and Colorectal Cancer Group" with 1 trials as a collaborator, "Foundation Medicine, Inc." with 1 trials as a collaborator and "Genentech, Inc." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were
collaborators in the rest 7 trials.
Clinical Trials Conditions at Bacs-Kiskun Megyei Korhaz, SZTE AOK Oktato Korhaza, Onkoradiologiai Kozpont
According to Clinical.Site data, the most researched conditions in "Bacs-Kiskun Megyei Korhaz, SZTE AOK Oktato Korhaza, Onkoradiologiai Kozpont" are
"Breast Cancer" (4 trials), "Colorectal Cancer" (2 trials), "Advanced Breast Cancer" (1 trials), "Cancer of Unknown Primary Site" (1 trials) and "Carcinoma, Non-Small-Cell Lung" (1 trials). Many other conditions were trialed in "Bacs-Kiskun Megyei Korhaz, SZTE AOK Oktato Korhaza, Onkoradiologiai Kozpont" in a lesser frequency.
Clinical Trials Intervention Types at Bacs-Kiskun Megyei Korhaz, SZTE AOK Oktato Korhaza, Onkoradiologiai Kozpont
Most popular intervention types in "Bacs-Kiskun Megyei Korhaz, SZTE AOK Oktato Korhaza, Onkoradiologiai Kozpont" are "Drug" (13 trials), "Other" (3 trials), "Biological" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.
The name of intervention was led by "Bevacizumab" (4 trials), "Capecitabine" (3 trials), "Paclitaxel" (3 trials), "Atezolizumab" (2 trials) and "Carboplatin" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Bacs-Kiskun Megyei Korhaz, SZTE AOK Oktato Korhaza, Onkoradiologiai Kozpont
The vast majority of trials in "Bacs-Kiskun Megyei Korhaz, SZTE AOK Oktato Korhaza, Onkoradiologiai Kozpont" are
10 trials for "All" genders and 4 trials for "Female" genders.
Clinical Trials Status at Bacs-Kiskun Megyei Korhaz, SZTE AOK Oktato Korhaza, Onkoradiologiai Kozpont
Currently, there are NaN active trials in "Bacs-Kiskun Megyei Korhaz, SZTE AOK Oktato Korhaza, Onkoradiologiai Kozpont".
undefined are not yet recruiting,
undefined are recruiting,
4 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 9 completed trials in Bacs-Kiskun Megyei Korhaz, SZTE AOK Oktato Korhaza, Onkoradiologiai Kozpont,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Bacs-Kiskun Megyei Korhaz, SZTE AOK Oktato Korhaza, Onkoradiologiai Kozpont, 0 "Phase 1"
clinical trials were conducted, 4 "Phase 2" clinical
trials and 7 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".